BioSpace News Archive

Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today reported financial results for the second quarter of the fiscal year 2024 ended March 31, 2024.

Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent corporate and clinical updates.

Travere Therapeutics, Inc. announced that on May 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 51,500 shares of its common stock to five new employees, consisting of inducement stock options to purchase an aggregate of 25,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 26,500 shares of its common stock.

According to Latest Study, the Europe active pharmaceutical ingredients (API) market size was estimated at USD 45.43 billion in 2023 and it is expected to grow at a CAGR of 5.78% from 2024 to 2033, to reach around USD 79.69 billion by 2033.

Mdxhealth SA announced that Michael K. McGarrity, Chief Executive Officer, will participate in the following investor conferences in June 2024.

STRATA Skin Sciences, Inc. announces its financial results for the quarter ended March 31, 2024 and provides a corporate update.

Cidara Therapeutics, Inc. announced that on May 14, 2024 it received a letter from the Listing Qualifications Department staff of the Nasdaq Stock Market LLC notifying the Company that it has regained compliance with Nasdaq’s requirements for continued listing.

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended March 31, 2024, and provided recent pipeline and business updates.

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the first quarter ended March 31, 2024 and other recent business developments.

Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies in oncology that address cancer immune resistance, announced today financial results for the three months ended March 31, 2024 and provided a corporate update.